Hengrui Pharmaceutical announced that recently, injectable Ruikang Luzetutamab from Suzhou Shengdia Biomedical Co., Ltd., a subsidiary of the company, was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. It is intended to be used in combination with bevacizumab to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations. Up to now, the total R&D investment for related projects is about 355 million yuan.

Hengrui Pharmaceutical announced that recently, injectable Ruikang Luzetutamab from Suzhou Shengdia Biomedical Co., Ltd., a subsidiary of the company, was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. It is intended to be used in combination with bevacizumab to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations. Up to now, the total R&D investment for related projects is about 355 million yuan.